Drugmakers unveil potential alternatives to Januvia

06/8/2008 | Bloomberg11

Companies developing a new class of diabetes drugs known as DPP-4 inhibitors have presented possible alternatives to Januvia, an FDA-approved treatment from Merck & Co., at the American Diabetes Association meeting. Researchers said that saxagliptin, Bristol-Myers Squibb Co. and AstraZeneca's candidate, helped more than one-third of patients reach the recommended glucose level in a six-month study. A combination of Takeda Pharmaceutical Co.'s alogliptin and Actos, an older drug, reduced glucose levels better than placebo and seemed as effective as Januvia, analysts said.

View Full Article in:

Bloomberg11

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY